EP0450102A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Nucleoside derivative
Assignee: Yamasa Shoyu KK
•
Filing: 1990-10-25
•
Granted: —
•
Expires: 2010-10-25
Abstract
Abstract Nucleoside derivatives having a potent antiprotozoan activity and a reduced adverse effect and being effective in treating diseases caused by protozoan, such as 2'- and/or 5'-acylated, aralkylated or silylated 3'-deoxyinosine; allopurinol 3'-deoxyriboside; 2'- and/or 5'-acylated, aralkylated or silylated allopurinol 3'-deoxyriboside; and 2'-, 3'-, and/or 5'-acylated, aralkylated or silylated allopurinol riboside.
Inventors
- 👤 Akira 10-501 Minamishinkawa Koumin Matsuda
- 👤 Yusuke Wataya
- 👤 Akira Ishii
- 👤 Tohru Ueda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 02:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/23; C07H23/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
161 words
A nucleoside derivative represented by Formula [I] [wherein A and B are different, and are each a carbon atom or a nitrogen atom, Y is a hydrogen atom, a hydroxyl group or -OR, and R's are the same or different, and are each a hydrogen atom, an aralkyl group, a silyl group or an acyl group, with the exception of the compounds represented by the following combinations: (1) A is a nitrogen atom, B is a carbon atom, Y is a hydroxyl group or -OR, and R's are the same or different, and are each a hydrogen atom, an aralkyl group, a silyl group or an acyl group, (2) A is a nitrogen atom, B is a carbon atom, Y is a hydrogen atom, and all R's are hydrogen atoms simultaneously, and (3) A is a carbon atom, B is a nitrogen atom, Y is a hydroxyl group, and all R's are hydrogen atoms simultaneously], or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
64 words
The nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 1 which is a nucleoside derivative represented by Formula [I'] (wherein R's are the same or different, and are each a hydrogen atom, an aralkyl group, a silyl group or an acyl group, with the exception of the compound in which all R's are hydrogen atoms simultaneously), or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
48 words
The nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 2 which is a nucleoside derivative selected from the group consisting of: a 5'-O-aralkyl-3'-deoxyinosine; a 2'-O-aralkyl-3'-deoxyinosine; a 2',5'-di-O-aralkyl-3'-deoxyinosine; a 5'-O-silyl-3'-deoxyinosine; a 2'-O-silyl-3'-deoxyinosine; a 2',5'-di-O-silyl-3'-deoxyinosine; a 5'-O-acyl-3'-deoxyinosine; a 2'-O-acyl-3'-deoxyinosine and a 2',5'-di-O-acyl-3'-deoxyinosine, or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
34 words
The nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 2 which is a nucleoside derivative selected from the group consisting of: 5'-O-benzyl-3'-deoxyinosine; 5'-O-stearoyl-3'-deoxyinosine; 2'-O-thexyldimethylsilyl-3'-deoxyinosine and 2'-O-tert-butyldimethylsilyl-3'-deoxyinosine, or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
81 words
The nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 1 which is a nucleoside derivative represented by Formula [I''] (wherein Y is a hydrogen atom, a hydroxyl group or -OR, and R's are the same or different, and are each a hydrogen atom, an aralkyl group, a silyl group or an acyl group, with the exception of the compound in which Y is a hydroxyl group and all R's are hydrogen atoms simultaneously), or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
50 words
The nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 5 which is a nucleoside derivative selected from the group consisting of: a 1-(β-D-2,5-di-O-acyl-3-deoxyribofuranosyl)allopurinol; a 1-(β-D-2,3,5-tri-O-acylribofuranosyl)allopurinol; a 1-(β-D-5-O-acyl-3-deoxyribofuranosyl)allopurinol; a 1-(β-D-5-O-acylribofuranosyl)allopurinol; a 1-(β-D-5-O-aralkyl-3-deoxyribofuranosyl)allopurinol; a 1-(β-D-5-O-aralkylribofuranosyl)allopurinol; a 1-(β-D-2-O-silylribofuranosyl)allopurinol; a 1-(β-D-2-O-silyl-3-deoxyribofuranosyl)allopurinol; a 1-(β-D-3-deoxyribofuranosyl)allopurinol and a 1-(β-D-5-O-silyl-3-deoxyribofuranosyl)allopurinol, or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
22 words
An antiprotozoal agent which comprises containing as an effective ingredient the nucleoside derivative or the pharmaceutically acceptable salt thereof of Claim 1.
Claim 8
Dependent Claim
12 words
The antiprotozoal agent of Claim 7 which is an oral administration preparation.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.